Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub

• Published in: Pilot and feasibility studies Vol. 7; no. 1; p. 1
• Main Authors: Arden, M A, Hutchings, M, Whelan, P, Drabble, S J, Beever, D, Bradley, J M, Hind, D, Ainsworth, J, Maguire, C, Cantrill, H, O'Cathain, A, Wildman, M
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 04-01-2021; BioMed Central; BMC
• Subjects: Adherence; Adults; Analysis; Antibiotics; Behaviour change wheel; Cystic fibrosis; Digital intervention; Drug therapy; Habits; Intervention; Intervention development; Patient compliance; Person-based approach; Semiconductor industry; Taxonomy; United States; United Kingdom; United Kingdom > UK; Adherence; Person-based approach; Intervention development; Cystic fibrosis; Digital intervention; Behaviour change wheel; Habit formation
• ISSN: 2055-5784; 2055-5784
• DOI: 10.1186/s40814-020-00739-2

Cystic fibrosis (CF) is a life-limiting genetic condition in which daily therapies to maintain lung health are critical, yet treatment adherence is low. Previous interventions to increase adherence have been largely unsuccessful and this is likely due to a lack of focus on behavioural evidence and theory alongside input from people with CF. This intervention is based on a digital platform that collects and displays objective nebuliser adherence data. The purpose of this paper is to identify the specific components of an intervention to increase and maintain adherence to nebuliser treatments in adults with CF with a focus on reducing effort and treatment burden.
Intervention development was informed by the Behaviour Change Wheel (BCW) and person-based approach (PBA). A multidisciplinary team conducted qualitative research to inform a needs analysis, selected, and refined intervention components and methods of delivery, mapped adherence-related barriers and facilitators, associated intervention functions and behaviour change techniques, and utilised iterative feedback to develop and refine content and processes.
Results indicated that people with CF need to understand their treatment, be able to monitor adherence, have treatment goals and feedback and confidence in their ability to adhere, have a treatment plan to develop habits for treatment, and be able to solve problems around treatment adherence. Behaviour change techniques were selected to address each of these needs and were incorporated into the digital intervention developed iteratively, alongside a manual and training for health professionals. Feedback from people with CF and clinicians helped to refine the intervention which could be tailored to individual patient needs.
The intervention development process is underpinned by a strong theoretical framework and evidence base and was developed by a multidisciplinary team with a range of skills and expertise integrated with substantial input from patients and clinicians. This multifaceted development strategy has ensured that the intervention is usable and acceptable to people with CF and clinicians, providing the best chance of success in supporting people with CF with different needs to increase and maintain their adherence. The intervention is being tested in a randomised controlled trial across 19 UK sites.